$IMMU - $TDOC - On our trading list with news today or analyst comments with our opinion & trade ideas. Immunomedics has it's price target raised by 2 analysts after releasing positive drug data. Teladoc is initiated at a buy with a lofty $250 price target.Immunomedics price target raised to $55 from $40 at Piper SandlerPiper Sandler analyst Joseph Catanzaro raised the firm's price target on Immunomedics to $55 from $40 after ASCENT trial data that he tells investors "came in about good as possible." The median progression free survival for Trodelvy in the third-line setting of 5.6 months was "remarkably on par" with first-line chemo, added Catanzaro, who said he now has added confidence that the TROPiCS-02 study "has a very high chance of success." He keeps an Overweight rating on Immunomedics shares.Immunomedics price target raised to $55 from $41 at Wells FargoWells Fargo analyst Jim Birchenough raised the firm's price target on Immunomedics to $55 from $41 and reiterates an Overweight rating on the shares citing the "better than expected" detail from the ASCENT study of Trodelvy in triple negative breast cancer. With extended progression-free survival benefit and positive overall survival data, Trodelvy adoption should be more rapid, used earlier, and the barrier to competitors is now greater, Birchenough tells investors in a research note.Our Take: IMMU has been a big winner for us this year - more than doubled! Trial data is coming in better than expected/as good as it can get. More upside and possible buyout in their future. $IMMU, Immunomedics, Inc. / H1 Teladoc initiated with an Overweight at StephensStephens analyst Scott Schoenhaus initiated coverage of Teladoc with an Overweight rating and $250 price target. Despite the valuation premium to peers, Teladoc remains attractive at current share levels given its the "large and ever-growing" addressable market, leading position in the telehealth industry and profitability and free cash flow trajectory, Schoenhaus tells investors in a research note. The analyst expects Teladoc to continue to lead the industry and grow market share.Our Take: A good longer-term healthcare pick. Getting a bit lofty right now though as this has run up in a big way already.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .